MetaCap

Ironwood Pharmaceuticals (IRWD) vs Oric Pharmaceuticals (ORIC)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Ironwood Pharmaceuticals (IRWD) has outperformed Oric Pharmaceuticals (ORIC) over the past year, gaining 48.7% versus a loss of 36.7%. Over five years, ORIC leads with a -48.6% price change compared with -57.9% for IRWD. Ironwood Pharmaceuticals is the larger company by market cap ($778.1 million vs $764.9 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IRWD+48.73%ORIC-36.66%
+76%+17%-42%
Nov 21, 20251 yearNov 20, 2026
IRWD-59.83%ORIC-55.39%
+37%-32%-101%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IRWD versus ORIC key metrics
MetricIRWDORIC
Share price$4.70$7.36
Market cap$778.09M$764.94M
1-day change-0.21%-4.42%
YTD return+39.47%-10.02%
1-year return+48.73%-36.66%
5-year return-57.89%-48.64%
P/E ratio (TTM)5.22—
Forward P/E3.00—
EPS (TTM)$0.90$-1.44
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$296.15M—
Revenue growth (YoY)-15.72%—
Net income (latest FY)$24.02M$-129.47M
Operating margin33.26%—
Net margin8.11%—
52-week high$5.78$14.68
52-week low$2.95$7.23
Distance from 52-week high-18.69%-49.86%
Analyst consensusbuystrong_buy
Avg. price target upside+31.49%+194.97%
Average volume2.15M1.59M
Shares outstanding165.55M103.93M
Employees100111
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IRWD has outperformed ORIC by 85.4 percentage points over the past year.

About Ironwood Pharmaceuticals

IRWD stock →

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.

Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees

About Oric Pharmaceuticals

ORIC stock →

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study.

Health Care · Biotechnology: Pharmaceutical Preparations · 111 employees

IRWD vs ORIC FAQ

Which is bigger, Ironwood Pharmaceuticals or Oric Pharmaceuticals?

Ironwood Pharmaceuticals (IRWD) is larger, with a market capitalization of $778.09M compared with $764.94M for Oric Pharmaceuticals (ORIC).

Which stock has performed better over the past year, IRWD or ORIC?

IRWD returned +48.73% over the past 12 months, compared with -36.66% for ORIC (price return, excluding dividends). Past performance does not predict future results.

Are Ironwood Pharmaceuticals and Oric Pharmaceuticals in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons